The existence of intermediate-penetrance variants in high-risk genes has been described by the ENIGMA consortium; the missense variant c.5096G>A (p.Arg1699Gln) in BRCA1 has been demonstrated to be associated with a lower risk of breast and ovarian cancer than truncating variants [33]. The gene discussed is BRCA1; the disease is ovarian carcinoma.